Contraception
Conditions
Keywords
Contraception, Hormonal patch, Norelgestromine, Ethinyl estradiol
Brief summary
The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).
Detailed description
A multicenter, open label, descriptive study. Five hundred requiring contraception will receive the weekly transdermal contraceptive patch for 6 cycles. At the baseline and after the 1st, 3rd and 6th cycles, satisfaction with the method will be assessed. The contraceptive efficacy will be assessed by the Pearl Index and by life table analysis. To assess satisfaction with the weekly transdermal contraceptive patch, this method will be compared to the previous contraceptive method. Adhesion, cycle control, safety and efficacy are secondary outcomes. Treatment duration: 6 cycles (4 weeks each). The subject will wear a 20 cm2 contraceptive transdermal patch for one full week, apply a fresh patch for week 2, and a third patch for week 3. The fourth week will be patch-free. Each patch deliveries 150 mcg of NLGM and 20 mcg of EE per day.
Interventions
DRUGNorelgestromine (NLGM)/ethinyl estradiol (EE)
Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
Sponsors
Janssen-Cilag Farmaceutica Ltda.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult females who meet the following selection criteria: Have regular menses occuring every 25-35 days * Acceptable body mass (\< 30) and the weight is \< 90 kg * Has completed her last term pregnancy at least 4 months prior to study admission, is not lactating and has at least one normal menstrual period since her last pregnancy and not breast feeding * Has a sitting blood pressure systolic \< 140 mm/Hg and diastolic \< 90 mm/Hg.
Exclusion criteria
* Has not received a DepoProvera injection or any other depot hormone injection within six months prior to the screening visit * Has not used / or in current use of barbiturates, antiepileptics, rifampin, griseofulvin, Hypericum perforatum, or other hepatic enzyme-inducing drugs within 30 days prior to the pre-study visit * Has not a uncontrolled disorder * No women over the age 35 who smoke.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pregnancy Rate Determined by Pearl Index | Cycle 6 (Day 168) | Pearl Index is the number of pregnancies with use of therapy divided by the number of cycles with therapy use. It is an estimation of the number of pregnancies per 100 woman-years of product use. |
| Pregnancy Rate Determined by Table of Life Analysis | Cycle 6 (Day 168) | Pregnancy rate was determined by table of life analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Breakthrough Bleeding and/or Spotting | Day 28 of Cycle 1, 3 and 6 | Percentage of participants with breakthrough bleeding and/or spotting was reported. |
| Compliance Score | Day 28 of Cycle 1, 2, 3, 4, 5 and 6 | Score of compliance was calculated for each participant by dividing the number of cycles with at least one day without the study drug by the total number of therapy cycles. Average score was calculated for cycle 1 to 6. |
| Percentage of Participants With Response to Satisfaction Questionnaire | Day 28 of Cycle 1, 3 and 6 | Percentage of participants with response to satisfaction questionnaire was reported for following categories: previous contraceptive, method election, physical well-being, emotional well-being, intermenstrual bleeding and intensity, menstrual flow volume, pre-menstrual symptoms, and easiness in ethinyl estradiol and norelgestromin transdermal patch use. |
Countries
Brazil, Mexico
Outcome results
None listed